Article Sidebar
Views pdf: 96
EVALUATION OF THE VALUE OF TISSUE MICROARRAY (TMA) TECHNIQUE IN ASSESSING P53 PROTEIN EXPRESSION IN ENDOMETRIAL CARCINOMA
Main Article Content
Abstract
Background: Endometrial carcinoma (EC) is one of the most common malignancies in women, with the p53-mutant molecular subgroup associated with the poorest prognosis. Immunohistochemistry (IHC) is an effective method for assessing p53 expression. The tissue microarray (TMA) technique enables simultaneous analysis of multiple tissue samples in a cost- and time-efficient manner. Objective: To evaluate p53 protein expression using IHC and compare results between TMA cores and conventional surgical specimens. Subjects and Methods: A cross-sectional descriptive study was conducted on 112 endometrial carcinoma samples at Ho Chi Minh City Oncology Hospital. Histopathological features, including histologic type and grade, were evaluated on hematoxylin and eosin-stained slides. IHC staining for p53 was performed on both TMA cores and surgical specimens, and concordance was assessed. Results: The mean age was 56.5 ± 10.71 years, with the >50-year-old group accounting for 76.8% of the cases. Endometrioid carcinoma was the predominant histologic subtype (79.46%, n = 89), with grade 2 comprising 40.45%, grade 3 at 38.20%, and grade 1 at 21.35%. Abnormal p53 expression was observed in 18.75% of surgical specimens and 19.4% of TMA samples. The concordance rate between the two methods was 98.2%, with a Kappa coefficient of 0.950 (standard error: 0.034; 95% confidence interval: 0.883–1.000; p < 0.001). Conclusion: Our study demonstrates that the TMA technique has a high concordance with surgical specimens in evaluating p53 expression, supporting its applicability in both research and routine pathology practice.
Article Details
Keywords
endometrial carcinoma, p53 protein, immunohistochemistry, tissue microarray
References
2. Höhn, A.K., et al., 2020 WHO Classification of Female Genital Tumors. Geburtshilfe Frauenheilkd, 2021. 81(10): p. 1145-1153.
3. Köbel, M., et al., Interpretation of P53 Immunohistochemistry in Endometrial Carcinomas: Toward Increased Reproducibility. Int J Gynecol Pathol, 2019. 38 Suppl 1(Iss 1 Suppl 1): p. S123-s131.
4. Huvila, J., et al., Subclonal p53 immunostaining in the diagnosis of endometrial carcinoma molecular subtype. Histopathology, 2023. 83(6): p. 880-890.
5. Nguyễn, K.D., Nghiên cứu một số yếu tố tiên lượng bệnh nhân ung thư nội mạc tử cung tại Bệnh viện K, in Luận văn Thạc sĩ Y học. 2021, Trường Đại học Y Hà Nội: Hà Nội.
6. Kommoss, S., et al., Final validation of the ProMisE molecular classifier for endometrial carcinoma in a large population-based case series. Ann Oncol, 2018. 29(5): p. 1180-1188.
7. Thompson EF, H.J., Jamieson A, Leung S, Lum A, Offman S, Lytwyn A, Sur ML, Hoang L, Irving J, van der Westhuizen N, Morin C, Bicamumpaka C, Azordegan N, Gougeon F, Ennour-Idrissi K, Senz J, McConechy MK, Aguirre-Hernandez R, Lui V, Kuo C, Bell C, Salisbury T, Lawson J, He E, Wang S, Chiu D, Kean S, Samouëlian V, Salvador S, Gotlieb W, Helpman L, Scott S, Wohlmuth C, Vicus D, Plante M, Talhouk A, Huntsman D, Parra-Herran C, Kinloch M, Grondin K, Gilks CB, McAlpine JN, Variability in endometrial carcinoma pathology practice: opportunities for improvement with molecular classification. Society of Gynecologic Oncologists of Canada (CoP, Translational Research), 2022 Dec. 35(12): p. (1974-1982).
8. Visser, N.C.M., et al., Tissue microarray is suitable for scientific biomarkers studies in endometrial cancer. Virchows Arch, 2018. 472(3): p. 407-413.
9. Ciesielska, U., et al., Comparison of TMA Technique and Routine Whole Slide Analysis in Evaluation of Proliferative Markers Expression in Laryngeal Squamous Cell Cancer. In Vivo, 2020. 34(6): p. 3263-3270.
10. Tạ, H.H.Đ., T.H. Ngô, and T.U. Lê, ứng dụng kỹ thuật sắp xếp dãy mô trong nghiên cứu các dấu ấn hóa mô miễn dịch ở u lympho tế bào b lớn lan tỏa. Tạp chí Y học Việt Nam, 2024. 538(1).